11:44 AM EST, 01/09/2025 (MT Newswires) -- Rapport Therapeutics ( RAPP ) said Thursday that preliminary analysis of data from positron emission tomography and the second multiple ascending dose trials for RAP-219 showed it achieved target receptor occupancy within five days of dosing.

The investigational drug also maintained a differentiated tolerability profile, according to the company.

The company is evaluating RAP-219 in patients with refractory focal epilepsy in a phase 2a proof-of-concept trial and expects topline results in mid-2025.

Price: 16.69, Change: -1.10, Percent Change: -6.16